A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer Clinical Trial

Official title:

A Multi-Center, Randomized, Double-Blind, Phase III Study of Platinum-Containing Chemotherapy With or Without CS1001 in Stage IV Non-Small Cell Lung Cancer Subjects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03789604
• Other study ID #: CS1001-302
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: December 13, 2018
• Est. completion date: June 30, 2025

Study information

• Verified date: July 2023
• Source: CStone Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 479
• Est. completion date: June 30, 2025
• Est. primary completion date: May 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Willing to participate in this trial; fully understand and informed of this trial, and able to provide written informed consent form (ICF).

2. 18-75 years of age (18 and 75 included) on the day of signing ICF.

3. Histologically or cytologically confirmed stage IV non-small cell lung cancer (staged according to the 8th International Association for the Study of Lung Cancer (IASLC) classification.

4. Subjects haven't received systemic treatment for advanced/metastatic NSCLC.

5. Measurable target lesion evaluated by investigators according to RECIST v1.1.

6. ECOG PS of 0-1.

7. Life expectancy = 12 weeks.

8. Subject with prior anti-cancer treatment can only be enrolled when all toxicities except for hearing loss, alopecia and fatigue, of prior anti-cancer treatment has recovered to = Grade 1 according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

9. Subjects must have adequate organ function.

10. Women of childbearing potential (WOBPC, as defined in section 13.5) must have a negative pregnancy test =7 days prior to the first dose of investigational product. WOBCP or fertile men and their WOBCP partners must agree to use an effective method of birth control from providing signed ICF and for 6 months after last dose of investigational product.

Exclusion Criteria:

1. Histologically confirmed small cell lung cancer or containing small cell component.

2. Subjects with current active autoimmune disease or prior history of autoimmune disease.

3. Malignancies other than NSCLC within 5 years prior to randomization.

4. Known history of human immunodefiency virus (HIV) infection and/or acquired immune deficiency syndrome.

5. Subject with active hepatitis B or hepatitis C.

6. Subjects with known history of alcoholism or drugs abuse.

7. Has a known hypersensitivity to any component of study treatment, for example pemetrexed, cisplatin, carboplatin or other platinum compounds.

8. Subjects with other conditions that in the investigator's opinion may influence subject's compliance or make subjects not suitable for participating in this trial.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Biological:
• CS1001 monoclonal antibody
Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
• CS1001 placebo
Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle

Locations

Country	Name	City	State
China	Shanghai Pulmonary Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
CStone Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS) in all subjects evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1		up to approximately 5 years
Secondary	Overall Survival (OS)	OS defined as the time from randomization to all-cause death.	up to approximately 7 years
Secondary	PFS assessed by BICR	PFS defined as the time from randomization to the first occurrence of disease progression or all-cause death (whichever occurs first), as determined by the BICR according to RECIST v1.1	up to approximately 5 years
Secondary	PFS in subgroup of participants with PD-L1 Expression=1%, as determined by the investigator	PFS after randomization as determined by the investigator according to RECIST v1.1 in the subgroup of patients with PD-L1 expression =1% defined by the SP263 immunohistochemistry (IHC) assay.	up to approximately 5 years
Secondary	Objective Response Rate (ORR) assessed by the investigator according to RECIST v1.1	ORR, defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions >=4 weeks apart, as determined by the investigator according to RECIST v1.1.	up to approximately 5 years
Secondary	Duration of response (DOR) assessed by the investigator according to RECIST v1.1	DOR defined as the time between the date of the earliest qualifying response and the date of progressive disease or all-cause death, whichever occurs first, as determined by the investigator according to RECIST v1.1.	up to approximately 5 years
Secondary	Safety and tolerability of CS1001 or placebo in combination with platinum-based chemotherapy		up to approximately 5 years
Secondary	Pharmacokinetics (PK) and immunogenecity of CS1001		up to approximately 5 years
Secondary	Efficacy of CS1001 monotherapy in subjects cross over to receive CS1001 who experienced progressive disease after assigned to the placebo group in the double-blind phase (CS1001 or placebo in combination with chemotherapy)		up to approximately 5 years